Taken together, these results show that SNX10 is required for glioblastoma growth in vivo and higher SNX10 expression portends worse prognosis in both glioma and glioblastoma patients, suggesting SNX10 as a potential therapeutic target with clinical utility for glioblastoma patients. The gene discussed is SNX10; the disease is glioma.